Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201.

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

PMID:
19403939
DOI:
10.1093/annonc/mdp201
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center